Ontology highlight
ABSTRACT:
SUBMITTER: Ledezma B
PROVIDER: S-EPMC3873235 | biostudies-other | 2013 Dec
REPOSITORIES: biostudies-other
Cancer management and research 20131221
After decades without promising new treatments for advanced and metastatic melanoma, ipilimumab was the first systemic therapy approved for use in this patient population. A fully human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen 4 (CTLA-4) to augment antitumor T-cell responses, ipilimumab significantly extended overall survival in clinical trials. Because ipilimumab is associated with a set of immune-related adverse events that likely reflect the agent's mechanism of action, ...[more]